Considerable decline in prostate cancer mortality in Nordic countries after 2000
DOI:
https://doi.org/10.2340/1651-226X.2025.41334Keywords:
Prostate cancer, Nordic countries, Mortality trendsAbstract
Background and purpose: In the late 1990s, the Nordic countries, with Norway at the top, were among the countries with the highest prostate cancer mortality in the world. We present updated mortality rates from the Nordic countries and discuss possible interpretations of changes in trends.
Material and methods: Age-standardized rates for prostate-specific mortality in 1985–2022, estimated lifetime risk of death (0–84 years) and annual changes in mortality were obtained from the NORDCAN database. Joinpoint regression was used to evaluate trend changes for the period 1985–2022. For comparison, rates from other European countries from 2022 were retrieved from the GLOBOCAN database.
Results: Between 1995–99 and 2018–22, mortality in men aged 40–84 years decreased from 38% in Denmark to 59% in Norway. By 2022 Norway had the second lowest mortality among the Nordic countries overall, and the lowest under 85 years. The life-time risk of dying from prostate cancer declined from 5.6–7.1% in 1995–99 to 3.1–4.2% in the last 5-year period. During the last years mortality has decreased most rapidly in Sweden (4.5% annually from 2016) and Norway (4.3% annually from 2014). The Nordic countries are no longer among the countries with the highest mortality in Europe.
Interpretation: Mortality from prostate cancer has decreased significantly in the Nordic countries over the last decades. Possible explanatory factors are likely to include improvements in prostate cancer management strategies and treatment.
Downloads
References
Hernes E, Harvei S, Glattre E, Gjertsen F, Fossa SD. High prostate cancer mortality in Norway: influence of cancer registry information? APMIS. 2005;113(7–8):542–9.
https://doi.org/10.1111/j.1600-0463.2005.apm_245.x DOI: https://doi.org/10.1111/j.1600-0463.2005.apm_245.x
Vaccarella S, Li M, Bray F, Kvale R, Serraino D, Lorenzoni V, et al. Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study. BMJ. 2024;386:e077738.
https://doi.org/10.1136/bmj-2023-077738 DOI: https://doi.org/10.1136/bmj-2023-077738
Bertuccio P, Santucci C, Carioli G, Malvezzi M, La Vecchia C, Negri E. Mortality trends from urologic cancers in Europe over the period 1980–2017 and a projection to 2025. Eur Urol Oncol. 2021;4(5):677–96.
https://doi.org/10.1016/j.euo.2021.05.005 DOI: https://doi.org/10.1016/j.euo.2021.05.005
Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, et al. NORDCAN – a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725–36.
https://doi.org/10.3109/02841861003782017 DOI: https://doi.org/10.3109/02841861003782017
Loffeler S, Halland A, Weedon-Fekjaer H, Nikitenko A, Ellingsen CL, Haug ES. High Norwegian prostate cancer mortality: evidence of over-reporting. Scand J Urol. 2018;52(2):122–8.
https://doi.org/10.1080/21681805.2017.1421260 DOI: https://doi.org/10.1080/21681805.2017.1421260
Fall K, Stromberg F, Rosell J, Andren O, Varenhorst E. South-East region prostate cancer G. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42(4):352–7.
https://doi.org/10.1080/00365590802078583 DOI: https://doi.org/10.1080/00365590802078583
Skyrud KD, Bray F, Moller B. A comparison of relative and cause-specific survival by cancer site, age and time since diagnosis. Int J Cancer. 2014;135(1):196–203.
https://doi.org/10.1002/ijc.28645 DOI: https://doi.org/10.1002/ijc.28645
Orrason AW, Styrke J, Garmo H, Stattin P. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU Int. 2023;131(4):486–93.
https://doi.org/10.1111/bju.15891 DOI: https://doi.org/10.1111/bju.15891
Joinpoint Regression Program VA. Statistical research and applications branch. National Cancer Institute; 2024. (Last accessed: 23 January 2025) Available from: https://surveillance.cancer.gov/joinpoint/
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2020. (Last accessed: 23 January 2025) Available from: https://gco.iarc.fr/today
Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52.
https://doi.org/10.1016/j.eururo.2019.08.005 DOI: https://doi.org/10.1016/j.eururo.2019.08.005
Kvale R, Myklebust TA, Engholm G, Heinavaara S, Wist E, Moller B. Prostate and breast cancer in four Nordic countries: a comparison of incidence and mortality trends across countries and age groups 1975–2013. Int J Cancer. 2017;141(11):2228–42.
https://doi.org/10.1002/ijc.30924 DOI: https://doi.org/10.1002/ijc.30924
Hugosson J, Roobol MJ, Mansson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76(1):43–51.
https://doi.org/10.1016/j.eururo.2019.02.009 DOI: https://doi.org/10.1016/j.eururo.2019.02.009
Kvale R, Auvinen A, Adami HO, Klint A, Hernes E, Moller B, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99(24):1881–7.
https://doi.org/10.1093/jnci/djm249 DOI: https://doi.org/10.1093/jnci/djm249
Report from the Norwegian Prostate Cancer Registry 2023. Norwegian. (Last accessed: 23 January 2025) Available from: https://www.kreftregisteret.no/Generelt/Rapporter/Arsrapport-fra-kvalitetsregistrene/Arsrapport-fra-prostatacancerregisteret-/
INCA – informationsnätverk för cancervården. Swedish. (Last accessed: 23 January 2025) Available from: https://statistik.incanet.se/npcr/
Cancer Registry of Norway. Norwegian Institute of Public Health. Cancer in Norway 2023 – cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2024. (Last accessed: 23 January 2025) Available from: https://www.kreftregisteret.no/Generelt/Rapporter/Cancer-in-Norway/cancer-in-norway-2023/
Hamdy FC, Donovan JL. Fifteen-year outcomes of the protect trial for localized prostate cancer reply. N Engl J Med. 2023;389(1):92.
https://doi.org/10.1056/NEJMc2306135 DOI: https://doi.org/10.1056/NEJMc2306135
Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–73.
https://doi.org/10.1016/S1470-2045(10)70223-0 DOI: https://doi.org/10.1016/S1470-2045(10)70223-0
Storås AH, Fosså SD, Ursin G, Andreassen BK. Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs. Prostate Cancer Prostatic Dis. 2023;26(1):53–8.
https://doi.org/10.1038/s41391-021-00445-x DOI: https://doi.org/10.1038/s41391-021-00445-x
Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M. Survival trend in individuals with De Novo metastatic prostate cancer after the introduction of Doublet therapy. JAMA Netw Open. 2023;6(10):e2336604.
https://doi.org/10.1001/jamanetworkopen.2023.36604 DOI: https://doi.org/10.1001/jamanetworkopen.2023.36604
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5.
https://doi.org/10.1200/JCO.2007.12.4008 DOI: https://doi.org/10.1200/JCO.2007.12.4008
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.
https://doi.org/10.1016/S1470-2045(14)71205-7 DOI: https://doi.org/10.1016/S1470-2045(14)71205-7
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.
https://doi.org/10.1056/NEJMoa1213755 DOI: https://doi.org/10.1056/NEJMoa1213755
Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877–92.
https://doi.org/10.1016/j.euo.2021.09.006 DOI: https://doi.org/10.1016/j.euo.2021.09.006
Reas DL, Nygård JF, Svensson E, Sørensen T, Sandanger I. Changes in body mass index by age, gender, and socio-economic status among a cohort of Norwegian men and women (1990–2001). BMC Public Health. 2007;7:269.
https://doi.org/10.1186/1471-2458-7-269 DOI: https://doi.org/10.1186/1471-2458-7-269
Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol. 2014;66(6):1054–64.
https://doi.org/10.1016/j.eururo.2014.08.059 DOI: https://doi.org/10.1016/j.eururo.2014.08.059
Drost FH, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Remmers S, et al. Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. Transl Androl Urol. 2018;7(1):98–105.
https://doi.org/10.21037/tau.2017.12.28 DOI: https://doi.org/10.21037/tau.2017.12.28
Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–22.
https://doi.org/10.1016/S0140-6736(16)32401-1 DOI: https://doi.org/10.1016/S0140-6736(16)32401-1
Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767–77.
https://doi.org/10.1056/NEJMoa1801993 DOI: https://doi.org/10.1056/NEJMoa1801993
Council recommendation on strengthening prevention through early detection: a new EU approach on cancer screening. (Last accessed: 23 January 2025) Available from: https://health.ec.europa.eu/system/files/2022-09/com_2022-474_act_en.pdf
Bratt O, Godtman RA, Jiborn T, Wallstrom J, Akre O, Carlsson S, et al. Population-based organised prostate cancer testing: results from the first invitation of 50-year-old men. Eur Urol. 2024;85(3):207–14.
https://doi.org/10.1016/j.eururo.2023.11.013 DOI: https://doi.org/10.1016/j.eururo.2023.11.013
Current evidence and ongoing projects in screening programmes. The Swedish experience: OPT trial. Godtman RA. EMUC24 – 16th European Multidisciplinary Congress on Urological Cancers. Webcast. (Last accessed: 23 January 2025) Available from: https://urosource.uroweb.org/resource-centres/EMUC24/261392/webcast
Organisert prostatakrefttesting, Norsk urologisk forenings standpunkt anno 2022. Norwegian. (Last accessed: 23 January 2025) Available from: https://www.legeforeningen.no/contentassets/259450f0ae0d412f96583acf215b7e26/otp_vedlegg-1_final.pdf
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447–60.
https://doi.org/10.1016/S0140-6736(21)02437-5 DOI: https://doi.org/10.1016/S0140-6736(21)02437-5
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.
https://doi.org/10.1056/NEJMoa1503747 DOI: https://doi.org/10.1056/NEJMoa1503747
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.
https://doi.org/10.1056/NEJMoa1405095 DOI: https://doi.org/10.1056/NEJMoa1405095
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.
https://doi.org/10.1056/NEJMoa1702900 DOI: https://doi.org/10.1056/NEJMoa1702900
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022;399
(10336):1695–707.
https://doi.org/10.1016/S0140-6736(22)00367-1 DOI: https://doi.org/10.1016/S0140-6736(22)00367-1
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–66.
https://doi.org/10.1016/S0140-6736(18)32486-3 DOI: https://doi.org/10.1016/S0140-6736(18)32486-3
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with Olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345–57.
https://doi.org/10.1056/NEJMoa2022485 DOI: https://doi.org/10.1056/NEJMoa2022485
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103.
https://doi.org/10.1056/NEJMoa2107322 DOI: https://doi.org/10.1056/NEJMoa2107322
Published
How to Cite
License
Copyright (c) 2025 Rune Kvåle, Giske Ursin, Christian Ekanger, Bjørn Møller
This work is licensed under a Creative Commons Attribution 4.0 International License.
